Jazz Pharmaceuticals (JAZZ) Capital Expenditures (2010 - 2026)

Jazz Pharmaceuticals' Capital Expenditures history runs 17 years deep, the most recent figure standing at $77.2 million for Q1 2026.

• On a quarterly basis, Capital Expenditures changed N/A year-over-year to $77.2 million in Q1 2026; TTM through Mar 2026 was $136.0 million, a 300.09% increase from a year earlier, with the FY2025 full-year figure at $58.8 million, up 54.33% from the prior year.
• Capital Expenditures grew to $77.2 million in Q1 2026 per JAZZ's latest filing, from -$799.3 million in the prior quarter.
• Across five years, Capital Expenditures topped out at $857.3 million in Q3 2025 and bottomed at -$799.3 million in Q4 2025.
• The 5-year median for Capital Expenditures is $4.2 million (2022), against an average of $12.4 million.
• Biggest YoY gain for Capital Expenditures was 7846.34% in 2025; the steepest drop was 6115.66% in 2025.
• Year by year, Capital Expenditures stood at $4.4 million in 2022, then slumped by 417.16% to -$13.9 million in 2023, then surged by 195.87% to $13.3 million in 2024, then slumped by 6115.66% to -$799.3 million in 2025, then jumped by 109.66% to $77.2 million in 2026.
• Per Business Quant, the three latest JAZZ Capital Expenditures figures stand at $77.2 million (Q1 2026), -$799.3 million (Q4 2025), and $857.3 million (Q3 2025).